BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20008547)

  • 1. Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist.
    Aguirre SA; Huang W; Prasanna G; Jessen B
    Toxicol Pathol; 2009 Dec; 37(7):911-20. PubMed ID: 20008547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.
    Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M; Nair S; Rui E; Lafontaine J; Almaden CD; Wells P; Krauss A
    Exp Eye Res; 2009 Nov; 89(5):608-17. PubMed ID: 19445930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D; Almaden C; Fortner J; Toris C; Niesman M; Lafontaine J; Krauss A
    Exp Eye Res; 2011 Sep; 93(3):256-64. PubMed ID: 21376717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
    Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
    J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists.
    Bhattacherjee P; Williams BS; Paterson CA
    Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):3047-53. PubMed ID: 10549672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist.
    Toyoda H; Terai H; Sasaoka R; Oda K; Takaoka K
    Bone; 2005 Oct; 37(4):555-62. PubMed ID: 16027058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prostanoid EP agonists on mouse intraocular pressure.
    Saeki T; Ota T; Aihara M; Araie M
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2201-8. PubMed ID: 19117925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization.
    BenEzra D; Griffin BW; Maftzir G; Sharif NA; Clark AF
    Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):1954-62. PubMed ID: 9331259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate.
    Sekiguchi M; Konno S; Kikuchi S
    Spine (Phila Pa 1976); 2006 Apr; 31(8):869-72. PubMed ID: 16622373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
    Chan P
    Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.
    Plummer CE; MacKay EO; Gelatt KN
    Vet Ophthalmol; 2006; 9(4):245-9. PubMed ID: 16771760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of topical ocular corticosteroid administration in dogs with experimentally induced latent canine herpesvirus-1 infection.
    Ledbetter EC; Kice NC; Matusow RB; Dubovi EJ; Kim SG
    Exp Eye Res; 2010 Jun; 90(6):711-7. PubMed ID: 20223234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y; Kawazu K
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E receptor subtype EP4 agonist protects cochleae against noise-induced trauma.
    Hori R; Nakagawa T; Sugimoto Y; Sakamoto T; Yamamoto N; Hamaguchi K; Ito J
    Neuroscience; 2009 Jun; 160(4):813-9. PubMed ID: 19303430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
    Woodward DF; Chan MF; Cheng-Bennett A; Wheeler LA; Chen G; Burke JA; Kharlamb A; Lai RK; Shan T
    Exp Eye Res; 1996 Oct; 63(4):411-23. PubMed ID: 8944548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive observations on eyes of cats after long-term maintenance of reduced intraocular pressure by topical application of prostaglandin E2.
    Bito LZ; Srinivasan BD; Baroody RA; Schubert H
    Invest Ophthalmol Vis Sci; 1983 Mar; 24(3):376-80. PubMed ID: 6572618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors.
    Takeuchi K; Tanigami M; Amagase K; Ochi A; Okuda S; Hatazawa R
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S67-74. PubMed ID: 20586869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.